Athena Amini, DNP

Athena Amini practices at Trustees of Columbia University in the City of New York in New York, New York.

Athena Amini's NPI, 1033632138, was assigned on July 20, 2017. Athena Amini holds New York license 342761.

Athena Amini's primary practice is Trustees of Columbia University in the City of New York, at 710 W 168th St, New York, NY 10032 in New York County. The practice phone is (646) 317-7111.

Athena Amini's primary practice is Trustees of Columbia University in the City of New York in New York, New York. Athena Amini is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Athena Amini to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Athena Amini practices, 3 sites in all. Vendor and product names are available with a free account.

Family is Athena Amini's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Dmand AI has Athena Amini's licenses on file in 2 states: New York and New Jersey.

Dmand AI lists epilepsy, insomnia and sleep apnea among the conditions Athena Amini treats.

CMS data shows 215 Medicare services from Athena Amini across 3 procedure codes in 2024, for 73 Medicare patients. Medicare paid $13,080 for them. Every service was in an office.

CMS counts 73 Medicare patients who saw Athena Amini in 2024. The largest group is 65 to 74, with 31 patients. 74% of them have high cholesterol, and 73% have high blood pressure. 26% are also on Medicaid. Their average risk score is 1.26, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Athena Amini's median patient age at 54, with 44% women.

In 2024, Athena Amini wrote 1,463 Medicare Part D claims for 250 patients. 86% of them were for generic drugs. CMS names the drug for 1,248 of them, across 25 drugs with 11 or more claims each, at $212,013 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Athena Amini for performance year 2024, reported through an alternative payment model (APM). Athena Amini accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Athena Amini as offering telehealth.

CMS Open Payments shows 3 general payments to Athena Amini from 1 drug or device company in 2025. Food and beverage make up the largest share, 73% of the total. LivaNova USA, Inc. paid the most, $908.